| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/06/2002 | WO2001095946A3 Combination product for carrying out a cytotoxic treatment in a mammal |
| 09/06/2002 | WO2001095937A3 Phytoestrogenic isoflavone compositions |
| 09/06/2002 | WO2001091805A3 Compounds for targeting endothelial cells |
| 09/06/2002 | WO2001082910A3 Combination of progesterone and mifepristone for cancer therapy |
| 09/06/2002 | WO2001080899A3 Rhamm peptide conjugates |
| 09/06/2002 | WO2001064738A3 Heparin-binding amino acid sequences derived from human proteins facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 09/06/2002 | WO2001012170A3 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| 09/06/2002 | WO2001002024A9 Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| 09/06/2002 | WO2000067761A9 Compositions and methods for identifying antigens which elicit an immune response |
| 09/06/2002 | CA2725635A1 Pharmaceutical salts of 6-dimethylaminomethyl-1-phenylcyclohexane compounds |
| 09/06/2002 | CA2440740A1 Hla ligand database utilizing predictive algorithms and methods of making and using same |
| 09/06/2002 | CA2439472A1 Methods and compositions for modifying apolipoprotein b mrna editing |
| 09/06/2002 | CA2439465A1 Prophylactic teat treatment |
| 09/06/2002 | CA2439376A1 Compositions and methods of manufacture for oral dissolvable dosage forms |
| 09/06/2002 | CA2439366A1 Pharmaceutical formulation comprising bicalutamide |
| 09/06/2002 | CA2439297A1 Compositions and methods for protecting tissues and cells from damage, and for repairing damaged tissues |
| 09/06/2002 | CA2439100A1 Eye drop |
| 09/06/2002 | CA2438824A1 Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same |
| 09/06/2002 | CA2438784A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 09/06/2002 | CA2438696A1 Polynucleotide formulation for enhanced intracellular transfer |
| 09/06/2002 | CA2438652A1 Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
| 09/06/2002 | CA2438630A1 Composition for freshening nostrils and sinus cavities |
| 09/06/2002 | CA2438268A1 Modulation of release from dry powder formulations |
| 09/06/2002 | CA2438204A1 Ascorbic acid analogs for metalloradiopharmaceuticals |
| 09/06/2002 | CA2438193A1 Novel dendritic polymers and their biomedical uses |
| 09/06/2002 | CA2438174A1 Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque |
| 09/06/2002 | CA2435815A1 Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer |
| 09/06/2002 | CA2435291A1 Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
| 09/06/2002 | CA2410802A1 A stable pharmaceutical formulation comprising torsemide modification ii |
| 09/05/2002 | US20020123609 Dendrimeric support or carrier macromolecule |
| 09/05/2002 | US20020123521 Such as triiodothyroacetic acid, triiodopropionic acid, 4-(2,6-dibromo-4-(1H-tetrazol-5-ylmethyl)-phenoxy)-2-isopropyl-phenol, and 4-(4-hydroxymethyl-2,6-diiodophenoxy)-2-iodo-phenol |
| 09/05/2002 | US20020123508 Cyclohexane carbocyclic ester derivative and cyclodextrin complex and composition for treatment of helicobacter pylori infections |
| 09/05/2002 | US20020123478 Synthetic transfection vectors |
| 09/05/2002 | US20020123476 For treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences |
| 09/05/2002 | US20020123473 For therapy of asthma |
| 09/05/2002 | US20020123466 GLP-1 formulations |
| 09/05/2002 | US20020123462 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 09/05/2002 | US20020123459 Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| 09/05/2002 | US20020123142 Generating cell culture; obtain cells, deposit on dextran beadlets, culture, separate cells from beadlets by digestion with dextranase |
| 09/05/2002 | US20020122833 Herbal compositions for treating immunological disorders |
| 09/05/2002 | US20020122820 Liposome having at least one recombinant soluble MHC-peptide complex incorporated therein; may also include at least one additional signal molecule for manipulating the intensity and quality of the immune response. |
| 09/05/2002 | US20020122818 Methods for isolation, quantification, characterization and modulation of antigen-specific T cells |
| 09/05/2002 | US20020122817 Solid instant-release forms of administration and process for producing the same |
| 09/05/2002 | US20020122810 Drugs specifically bound to synthetic receptors in such a manner that active drug becomes available only in the presence of a targeted pathophysiologic receptor. |
| 09/05/2002 | US20020122805 Molecular conjugate comprising (a) a photosensitizer and (b) a targeting moiety, wherein the targeting moiety targets the conjugate to the intracellular pathogen or to an infected host cell. |
| 09/05/2002 | US20020122793 Heparinase III and uses thereof |
| 09/05/2002 | US20020122785 Materials and processes for controlled release of thioamide moiety-containing therapeutic agents by linking to thiol-containing polymers |
| 09/05/2002 | US20020122769 Buffering reagents, chelating agents and stabilizers |
| 09/05/2002 | US20020121225 High levels of low viscosity propylene glycol alginate and a surfactant; does not retard the release of active ingredients from the coated substrate. |
| 09/05/2002 | DE10111163A1 Neue Siderophor-Antibiotikakonjugate mit 4- oder 6-zähnigen Eisenchelatoren auf der Basis von Aminosäuren oder Peptiden, Verfahren zu ihrer Herstellung und Ihre Anwendung New siderophore Antibiotikakonjugate with 4- or 6-dentate iron chelators on the basis of amino acids or peptides, process for their preparation and their use |
| 09/05/2002 | DE10111160A1 Neue Catecholat-ß-Laktamkonjugate, Verfahren zu ihrer Herstellung und ihre Anwendung New cathecolate ß-Laktamkonjugate, processes for their preparation and their use |
| 09/05/2002 | DE10109898A1 Lipide mit veränderlicher Ladung Lipids with variable charge |
| 09/05/2002 | DE10109763A1 Pharmazeutische Salze Pharmaceutical Salts |
| 09/05/2002 | DE10107737A1 Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie Use of a conjugate of IL-6 and an IL-6 receptor for tumor therapy |
| 09/05/2002 | DE10107663A1 Testosteronhaltiges transdermales therapeutisches System und Verfahren zu seiner Herstellung Testosterone-containing transdermal therapeutic system and process for its preparation |
| 09/05/2002 | DE10107659A1 Mucoadhäsive zerfallsfähige Arzneizubereitung zur Wirkstoffverabreichung in der Veterinär- und Humanmedizin Mucoadhesive disintegratable pharmaceutical preparation for drug delivery in veterinary and human medicine |
| 09/05/2002 | DE10106827A1 Verwendung eines Konjugats aus Interleukin-6(IL-6) und seinem Rezeptor zur Induktion der zellulären Expression des Stammzellfaktors (SCF) und von Flat-3-Ligand (Flt-3L) Use of a conjugate of interleukin-6 (IL-6) and its receptor in the induction of cellular expression of the stem cell factor (SCF) and Flat-3 ligand (Flt-3L) |
| 09/04/2002 | EP1236477A2 A formative agent of protein complex |
| 09/04/2002 | EP1236476A1 Medicinal compositions for oral use |
| 09/04/2002 | EP1236473A2 Self-assembling polynucleotide delivery system |
| 09/04/2002 | EP1236464A2 Cosmetic, dermatological or pharmaceutical composition without surfactants |
| 09/04/2002 | EP1236462A1 Multi-lamella based emulsion for stabilizing dermatologically useful ingredients and external preparation containing the same |
| 09/04/2002 | EP1235922A2 Excipient system that contains coating substances with enzymatically removable side-groups |
| 09/04/2002 | EP1235914A2 Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells |
| 09/04/2002 | EP1235900A1 Microparticle-based transfection and activation of dendritic cells |
| 09/04/2002 | EP1235893A2 Ether-capped poly(oxyalkylated) alcohol surfactants |
| 09/04/2002 | EP1235892A1 Compositions including ether-capped poly(oxyalkylated) alcohol surfactants |
| 09/04/2002 | EP1235779A2 Process for preparing ether-capped poly(oxyalkylated) alcohol surfactants |
| 09/04/2002 | EP1235639A1 Compositions including ether-capped poly(oxyalkylated) alcohol wetting agents |
| 09/04/2002 | EP1235618A2 Bioconjugation in vivo to pulmonary or blood components |
| 09/04/2002 | EP1235598A2 Compositions of a combination of radioactive therapy and cell-cycle inhibitors |
| 09/04/2002 | EP1235597A2 Nucleic acid delivery system |
| 09/04/2002 | EP1235596A2 Use of lytic toxins and toxin conjugates |
| 09/04/2002 | EP1235595A2 Integrin-mediated drug targeting |
| 09/04/2002 | EP1235594A2 Inhibition of secretion from non-neuronal cells |
| 09/04/2002 | EP1235579A1 Pharmaceutical compositions comprising trimegestone |
| 09/04/2002 | EP1235574A2 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 09/04/2002 | EP1235566A2 Valnemulin formulation |
| 09/04/2002 | EP1235562A1 Chronotherapeutic diltiazem formulations and the administration thereof |
| 09/04/2002 | EP1235560A2 Microchip devices for delivery of molecules and methods of fabrication thereof |
| 09/04/2002 | EP1235559A2 Solid oral dosage form |
| 09/04/2002 | EP1235558A2 Compressed tablet composition comprising a nsaid |
| 09/04/2002 | EP1235557A2 Gastroretentive controlled release pharmaceutical dosage forms |
| 09/04/2002 | EP1235555A2 Stable galenic preparations comprising a benzimidazol and method for the production thereof |
| 09/04/2002 | EP1175390A4 Disodium salts, monohydrates, and ethanol solvates |
| 09/04/2002 | EP1149066A4 Method of preparing alkylated salicylamides |
| 09/04/2002 | EP1098632A4 Charge reversal of polyion complexes |
| 09/04/2002 | EP1041975B1 Rate controlling membranes for controlled drug delivery devices |
| 09/04/2002 | EP1041972B1 Tablet for instant and prolonged release of one or more active substances |
| 09/04/2002 | EP0949923B1 Stabilised pharmaceutical compositions, based on quinupristine and dalfopristine, and their preparation |
| 09/04/2002 | EP0932389B1 Ophthalmic compositions containing a carbonic anhydrase inhibitor and xanthan gum |
| 09/04/2002 | EP0904063B1 Process for the preparation of microparticles |
| 09/04/2002 | EP0883602B1 Lipids |
| 09/04/2002 | EP0835098B1 New, stable medicinal compositions for generating propellant-free aerosols |
| 09/04/2002 | EP0814844B1 Thyroxine/cyclodextrin complexes and pharmaceutical compositions containing the same |
| 09/04/2002 | EP0801571B1 Soluble 2-chloro-2'-deoxyadenosine formulations |
| 09/04/2002 | EP0789590B1 Chitosan induced immunopotentiation |
| 09/04/2002 | EP0771209B1 Novel peptides |
| 09/04/2002 | EP0762896B1 Tocopherol compositions for delivery of biologically active agents |
| 09/04/2002 | EP0750515B1 Low molecular weight hyaluronic acid with peptide or protein |